Literature DB >> 11806282

[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].

K Bajou1, L Devy, V Masson, V Albert, F Frankenne, A Noël, J M Foidart.   

Abstract

The plasminogen/plasmin system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumour cell migration. High levels of components of the plasminogen activation system, and paradoxically also its inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been correlated with a poor prognosis for patients with cancers of different types. Recent findings clearly suggest that PAI-1 is essential for capillary sprouting during tumour angiogenesis. Moreover, there is accumulating evidence that both the urokinase receptor and PAI-1 are multifunctional proteins involved not only in extracellular matrix proteolysis but also in cellular adhesion and migration through their binding site for vitronectin. The understanding of whether PAI-1 plays a regulatory role in angiogenesis by tightly controlling proteolytic activity or by influencing cell migration could allow a new anti-angiogenic approach for tumour therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806282

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  3 in total

1.  Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.

Authors:  Siobhan L Webb; Andrew J Sanders; Malcolm D Mason; Wen G Jiang
Journal:  Mol Cell Biochem       Date:  2012-12-13       Impact factor: 3.396

2.  Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes.

Authors:  Véronique Masson; Laura Rodriguez de la Ballina; Carine Munaut; Ben Wielockx; Maud Jost; Catherine Maillard; Silvia Blacher; Khalid Bajou; Takeshi Itoh; Shige Itohara; Zena Werb; Claude Libert; Jean-Michel Foidart; Agnès Noël
Journal:  FASEB J       Date:  2004-11-18       Impact factor: 5.191

3.  Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.

Authors:  Yuqi Jing; Krisztina Kovacs; Vittal Kurisetty; Zhijie Jiang; Nick Tsinoremas; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2012-08-21       Impact factor: 5.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.